Lymphadenectomy In clinically early epitheLial ovArian Cancer and survival analysis (LILAC)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0010189

Enrollment

714

Registered

2025-02-13

Start date

2025-03-17

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : In the group of patients with ovarian cancer, lymphadenectomy is performed in the usual way under general anesthesia for the lymphadenectomy group (control group). Lymph node metas

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Women aged 20 years or older 2) Histologically confirmed epithelial ovarian cancer with no prior treatment 3) Clinical FIGO stage I/II diagnosis based on imaging (CT, MRI, or PET/CT) conducted within 4 weeks pre-surgery 4) Histological subtypes: High-grade serous (Grade 2/3), high-grade endometrioid (Grade 2/3), or clear cell carcinoma. Low-grade serous or endometrioid subtypes are eligible if clinical FIGO stage IC or higher is suspected. 5) Presumed FIGO stage I-II 6) Short axis of pelvic or para-aortic lymph nodes <15 mm on MRI or CT 7) Scheduled for re-staging surgery, with a requirement for adjuvant chemotherapy based on initial surgery findings 8) ECOG performance status 0-2 9) ASA physical status 1-2 10) Adequate organ function: WBC = 3,000/mm³ Platelets = 100,000/mm³ Creatinine = 2.0 mg/dL Bilirubin = 1.5 x institutional upper limit normal SGOT, SGPT, and ALP = 3 x institutional upper limit normal 11) Voluntary signed informed consent

Exclusion criteria

Exclusion criteria: 1) Presumed FIGO stage III-IV 2) Mucinous tumor histology 3) Non-epithelial ovarian tumors 4) Borderline ovarian tumors 5) Presence of lower extremity or perineal lymphedema 6) Clinically suspected lymph node metastasis during surgery (bulky nodes) 7) History of pelvic or para-aortic lymph node dissection 8) History of pelvic/abdominal radiotherapy 9) Prior chemotherapy for pelvic/abdominal tumors 10) Cancer other than non-melanoma skin cancer, cervical carcinoma in situ, T1 N0 M0 G1/2 breast cancer, or superficial bladder/gastric cancer within 5 years 11) Severe comorbidities or complications 12) Pregnant or breastfeeding women

Design outcomes

Primary

Measure	Time frame
3-year disease-free survival rate	—

Secondary

Measure	Time frame
overall survival rate;disease-free survival rate	—

Countries

Korea, Republic of

Contacts

Public ContactHeesu Jeong

KGOG(Korea Gynecologic Oncology Group)

jhsu422@kgog.org+82-2-6949-5362

Outcome results